As of October 22, 2026, Lakefront Biotherapeutics NV (LKFT) trades at $31.40. No model fair value is published for LKFT. LKFT reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — LKFT valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.
Reported EPS came in above the analyst estimate in 5 of the last 7 reports. The median share-price change across a report, in either direction, was 4.1%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Aug 10, 2026 | $-11.50 | $0.03 | +100.3% | +6.8% |
| May 6, 2026 | $-0.97 | $0.21 | +121.6% | +1.5% |
| Feb 23, 2026 | $-0.07 | $12.27 | +17628.6% | +1.4% |
| Nov 5, 2025 | $-0.28 | $-0.18 | +35.7% | +4.4% |
| Jul 23, 2025 | $-0.13 | $-0.93 | -615.4% | -7.3% |
| Apr 23, 2025 | $-0.18 | $0.97 | +638.9% | +3.9% |
| Feb 13, 2025 | — | $0.41 | — | +2.1% |
| Oct 30, 2024 | $-0.12 | $-0.74 | -516.7% | -7.5% |
Equity Rank's fundamental strength composite scores LKFT at 70.2/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, gross margin has moved -2.7 pp. Its SAVE composite score has moved +0.0 over the past 30 days.
LKFT reports its financial statements in EUR. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Lakefront Biotherapeutics NV (LKFT) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Lakefront Biotherapeutics NV (LKFT) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Biotechnology stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/LKFT. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.